Similar research indicates that NAT10, the only known “writer” of ac4C mRNA modification, is highly expressed in HNSC patients with lymph node metastasis, and this elevated expression is closely associated with poorer prognosis in patients. Here, NAT10 is linked to metastatic malignant neoplasm in the lymph nodes.